Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.36 |
| ▸ | PLK1 | P53350 | 13/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.34 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504909 | 0.79 | PLK1 (0.62) | PLK1 | |
| SCHEMBL2498645 | 0.79 | PLK1 (0.62) | KDRFGFR3PLK1FLT3NEK2 | |
| SCHEMBL2496391 | 0.78 | PLK1 (0.33) | PLK1PLK3PLK2 | |
| SCHEMBL2495476 | 0.78 | PLK1 (0.51) | PLK1FLT3PLK3PLK2 | |
| SCHEMBL2530345 | 0.76 | SALL4 (0.36) | KDRFGFR3PLK1FLT3 | |
| SCHEMBL2503592 | 0.75 | KDM4E (0.31) | PLK1 | |
| SCHEMBL2495147 | 0.75 | IRAK4 (0.40) | PLK1RIPK2 | |
| SCHEMBL2502787 | 0.74 | PIK3CA (0.46) | PLK1FLT3RIPK2 | |
| SCHEMBL2503598 | 0.72 | AKT1 (0.32) | — | |
| SCHEMBL2499008 | 0.71 | PLK1 (0.40) | PLK1PLK3PLK2RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | KDR 2002/4885FGFR3 1366/4885PLK1 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.